Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations

Annals of Thoracic Surgery

Volumn 65, Issue 1, 1998, Pages 70-77

  Dietrich, Wulf ^a   Schöpf, Karl ^a   Spannagl, Michael ^a   Jochum, Marianne ^a   Braun, Siegmund L ^a   Meisner, Hans ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; KALLIKREIN; PROTEINASE; PROTEINASE INHIBITOR; PROTHROMBIN; THROMBIN;

ADULT; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; OPEN HEART SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION;

EID: 0031907518     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)01123-5     Document Type: Conference Paper

References (32)

1. 1. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992;6: 76-100.
2. 2. Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med 1986;314:446-8.
3. 3. Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass induced platelet dysfunction - a scanning electron microscope study. Circulation 1992;86: 405-9.
4. 4. Van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
5. 5. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49:954-83.
6. 6. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
7. 7. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation pattern in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
8. 8. Lemmer JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations - efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107:543-53.
9. 9. Royston D, Taylor KM, Bidstrup BP, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
10. 10. Schonberger JP, Everts PA, Ercan H, et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving. Ann Thorac Surg 1992;54: 1172-6.
11. 11. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44.
12. 12. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization - a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
13. 13. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659-67.
14. 14. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery: a double-blind, placebo-controlled study. Anesthesiology 1995;83:679-89.
15. 15. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 1995;109:177-8.
16. 16. Feindt P, Volkmer I, Seyfert U, Huwer H, Kalweit G, Gams E. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation -changes under aprotinin therapy. Thorac Cardiovasc Surg 1993;41:9-15.
17. 17. Hunt BJ, Segal HC, Yacoub M. Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass [letter]. J Thorac Cardiovasc Surg 1992;104:211-2.
18. 18. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg 1996;62: 1575-7.
19. 19. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-20.
20. 20. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983;33:479-94.
21. 21. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-61.
22. 22. Spannagl M, Dietrich W, Beck A, Schramm W. High-dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization. Thromb Haemost 1994;72:159-60.
23. 23. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-8.
24. 24. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaardhansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-67.
25. 25. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-8.
26. 26. Kawasuji M, Ueyama K, Sakakibara N, et al. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 1993;55:1205-9.
27. 27. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 1993;82:3350-7.
28. 28. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997;113:194-201.
29. 29. Schulze K, Graeter T, Schaps D, Hausen B. Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement. Eur J Cardiothorac Surg 1993;7:495-6.
30. 30. Schonberger JP, Bredee JJ, van Oeveren W, et al. Preoperative therapy of low-dose aspirin in internal mammary artery bypass operations with and without low-dose aprotinin. J Thorac Cardiovasc Surg 1993;106:262-7.
31. 31. Alvarez JM, Quiney NF, McMillan D, et al. The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:29-33.
32. 32. Dietrich W. Shed mediastinal blood retransfusion should be used routinely in cardiac surgery - pro: shed mediastinal blood retransfusion should be used routinely in cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:95-9.